Having trouble accessing articles? Reset your cache.

MK-966 selective inhibitor of cyclooxygenase-2 data

In a dose-ranging trial of Merck's anti-inflammatory agent, 55-67 percent of patients with osteoarthritis of the hip and knee who

Read the full 200 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE